TP53 and colorectal carcinoma: To gain further insight into the potential for F10 to replace 5-FU for the treatment of CRC, we have undertaken a study investigating the relative potency of F10 and 5-FU towards four isogenic human CRC cell lines derived from HCT-116 but that differ in TP53 mutational status[21].